Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Rituximab Administration in Coronavirus Pandemic Era: A Mini-Review of Clinical Evidence Publisher



Shamabadi A1, 2 ; Mahmoudi H1 ; Daneshpazhooh M1
Authors

Source: Journal of Iranian Medical Council Published:2021


Abstract

Rituximab (RTX), as a B cell-depleting agent, is indicated in treating several malignancies and autoimmune diseases. The management of patients currently receiving RTX and patients starting the medication raised concerns in the pandemic era. Theoretically, suppressing the immune response at the beginning of coronavirus disease 2019 (COVID-19) enhances viral replication, but it prevents acute respiratory distress syndrome as the disease progresses. This review aims to investigate the results of RTX administration in patients during the pandemic era. There is insufficient evidence to definitively conclude on the safety of RTX during the pandemic. For this purpose, high-quality controlled cohort studies, as well as registry-based studies, would be helpful. © Eksperimental'naya i Klinicheskaya Gastroenterologiya 2020.
Other Related Docs
6. Anti-Ige Monoclonal Antibodies As Potential Treatment in Covid-19, Immunopharmacology and Immunotoxicology (2021)
9. Covid-19 in Patients With Cancer: Risks and Precautions, American Journal of Emergency Medicine (2021)
10. Covid-19 in Patients With Cancer, Advances in Experimental Medicine and Biology (2021)
12. Cytokines and Covid-19: Friends or Foes?, Human Vaccines and Immunotherapeutics (2020)
17. Current Evidence on the Use of Anakinra in Covid-19, International Immunopharmacology (2022)
20. Potential Therapeutic Approach of Intravenous Immunoglobulin Against Covid-19, Allergy# Asthma and Clinical Immunology (2021)